ATXN2L

Across TCGA pan-cancer cohorts, ATXN2L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATXN2L data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATXN2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATXN2L expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where ATXN2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.949	0.639	.009	22	view →
UCEC	DFS	Median	All	1.000	0.936	.023	10	view →
CCRCC	OS	Median	All	0.652	1.000	.008	8	view →
LSCC	DFS	Tertile	All	0.846	0.577	.018	7	view →
PDAC	OS	Tertile	III,IV	0.611	0.898	.018	6	view →
HNSC	DFS	Tertile	IV	1.000	0.883	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATXN2L–LUAD (DFS)

Open the LUAD breakdown →